Monoclonal anti-interleukin 2 (15-2) antibody binding to granular layer keratinocytes of human skin.
Among several monoclonal antibodies (moABs) directed against human interleukin 2 (IL-2), the 15-2 moAB raised in our laboratory against unglycosylated recombinant IL-2 (produced in Escherichia coli) cross-reacted with a human skin epitope. This moAB gave a strong staining on the cell-surface membranes of keratinocytes from the granular layer of the epidermis. In addition, the 15-2 moAB stained 15% of epidermal cell suspensions obtained from suction blisters and reacted with cells from the spinous layer in parakeratosis and psoriasis, as well as with spinous epithelioma cells. Preincubation of the 15-2 moAB with pure human recombinant IL-2 abrogated skin binding, whereas a polyclonal antikeratin antiserum did not block 15-2 skin binding. Two other anti-IL-2 moABs, one directed against unglycosylated recombinant IL-2 (17-2 moAB) and one against glycosylated natural IL-2 (9B11 IE5 moAB), were unreactive on skin. Taken together, the data suggest that the 15-2 moAB binds to an epitope cross-reacting with, but different from, IL-2 which is located in the cell-surface membranes of granular layer cells. This cross-reactive epitope may provide a useful probe for the study of human epidermal cell differentiation.
D000818:Animals; D000911:Antibodies, Monoclonal; D001666:Binding Sites, Antibody; D004817:Epidermis / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology* / Q000378:metabolism; D007633:Keratins; D051379:Mice; D008807:Mice, Inbred BALB C; D010241:Parakeratosis / Q000378:metabolism / Q000473:pathology; D011565:Psoriasis / Q000378:metabolism / Q000473:pathology; D013194:Staining and Labeling
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D007633:Keratins